JP2007529503A5 - - Google Patents

Download PDF

Info

Publication number
JP2007529503A5
JP2007529503A5 JP2007503444A JP2007503444A JP2007529503A5 JP 2007529503 A5 JP2007529503 A5 JP 2007529503A5 JP 2007503444 A JP2007503444 A JP 2007503444A JP 2007503444 A JP2007503444 A JP 2007503444A JP 2007529503 A5 JP2007529503 A5 JP 2007529503A5
Authority
JP
Japan
Prior art keywords
hib
vaccine
antigen
conjugate
protect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007503444A
Other languages
English (en)
Japanese (ja)
Other versions
JP4954056B2 (ja
JP2007529503A (ja
Filing date
Publication date
Priority claimed from GBGB0405787.3A external-priority patent/GB0405787D0/en
Application filed filed Critical
Publication of JP2007529503A publication Critical patent/JP2007529503A/ja
Publication of JP2007529503A5 publication Critical patent/JP2007529503A5/ja
Application granted granted Critical
Publication of JP4954056B2 publication Critical patent/JP4954056B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007503444A 2004-03-15 2005-03-14 低用量のHib結合体との組合せワクチン Expired - Fee Related JP4954056B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0405787.3 2004-03-15
GBGB0405787.3A GB0405787D0 (en) 2004-03-15 2004-03-15 Low dose vaccines
PCT/IB2005/000927 WO2005089794A2 (en) 2004-03-15 2005-03-14 Combination vaccines with low dose of hib conjugate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008056997A Division JP2008150397A (ja) 2004-03-15 2008-03-06 低用量のHib結合体との組合せワクチン

Publications (3)

Publication Number Publication Date
JP2007529503A JP2007529503A (ja) 2007-10-25
JP2007529503A5 true JP2007529503A5 (OSRAM) 2008-04-24
JP4954056B2 JP4954056B2 (ja) 2012-06-13

Family

ID=32117706

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007503444A Expired - Fee Related JP4954056B2 (ja) 2004-03-15 2005-03-14 低用量のHib結合体との組合せワクチン
JP2008056997A Pending JP2008150397A (ja) 2004-03-15 2008-03-06 低用量のHib結合体との組合せワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008056997A Pending JP2008150397A (ja) 2004-03-15 2008-03-06 低用量のHib結合体との組合せワクチン

Country Status (13)

Country Link
US (2) US20090208526A1 (OSRAM)
EP (1) EP1725258B1 (OSRAM)
JP (2) JP4954056B2 (OSRAM)
CN (2) CN102028944B (OSRAM)
AT (1) ATE480257T1 (OSRAM)
BR (1) BRPI0508813B8 (OSRAM)
CA (1) CA2559996C (OSRAM)
DE (1) DE602005023422D1 (OSRAM)
DK (1) DK1725258T3 (OSRAM)
GB (1) GB0405787D0 (OSRAM)
RU (1) RU2435609C2 (OSRAM)
SG (1) SG151253A1 (OSRAM)
WO (1) WO2005089794A2 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1296715T4 (en) * 2000-06-29 2016-03-07 Smithkline Beecham Biolog Multivalent vaccine composition.
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
LT2351578T (lt) 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
EA015964B1 (ru) 2006-09-07 2012-01-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
JP5637848B2 (ja) * 2007-06-04 2014-12-10 ノバルティス アーゲー 髄膜炎ワクチンの製剤化
CU23652A1 (es) * 2007-06-29 2011-05-27 Centro Inmunologia Molecular Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
WO2009133408A2 (en) * 2008-05-01 2009-11-05 Arecor Limited Protein formulation
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
PE20100366A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
CN102655879B (zh) * 2009-12-16 2016-03-09 印度血清研究所 疫苗组合物
MX343914B (es) 2010-09-01 2016-11-18 Glaxosmithkline Biologicals Sa Adsorcion de inmunopotenciadores en sales metalicas insolubles.
US20140112950A1 (en) * 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
JP6170906B2 (ja) 2011-04-21 2017-07-26 トラスティーズ・オブ・タフツ・カレッジTrustees Of Tufts College 活性物質を安定化させるための組成物および方法
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
AU2013338153B2 (en) * 2012-10-29 2018-06-21 The Board Of Trustees Of The University Of Arkansas Novel mucosal adjuvants and delivery systems
RU2626532C2 (ru) * 2015-01-16 2017-07-28 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Комбинированная вакцина для профилактики коклюша, дифтерии, столбняка, гепатита в и инфекции, вызываемой haemophilus influenzae тип в
EP3530285B1 (en) * 2016-10-20 2023-08-09 KM Biologics Co., Ltd. METHOD FOR PRODUCING HIB CONJUGATE VACCINE USING PRP WITH
LOWERED MOLECULAR WEIGHT
BR112020000999A2 (pt) 2017-07-18 2020-07-14 Serum Institute Of India Pvt Ltd. composição imunogênica tendo estabilidade aperfeiçoada, imunogenicidade melhorada e reatogenicidade reduzida e processo para a sua preparação
CN110251667A (zh) * 2018-05-11 2019-09-20 武汉博沃生物科技有限公司 一种免疫组合制剂及其制备方法和应用
CA3115803A1 (en) 2018-10-12 2020-04-16 Serum Institute Of India Private Ltd. Combination vaccine composition comprising reduced dose inactivated poliovirus and method for preparing the same
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition
CN118903397A (zh) * 2024-10-12 2024-11-08 成都迈科康生物科技有限公司 GloboH六糖、linker化合物、蛋白偶联物及免疫原性组合物在治疗或抑制上皮性肿瘤中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
US20020054884A1 (en) * 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
IL122588A (en) * 1995-06-23 2001-12-23 Smithkline Beecham Biolog A combination vaccine containing a polysaccharide conjugated antigen attached to a phosphate aluminum and one or more additional antibodies
DK1296715T4 (en) * 2000-06-29 2016-03-07 Smithkline Beecham Biolog Multivalent vaccine composition.

Similar Documents

Publication Publication Date Title
RU2006136212A (ru) КОМБИНИРОВАННЫЕ ВАКЦИНЫ С НИЗКОЙ ДОЗОЙ КОНЬЮГАТА Hib
CA1256250A (en) Covalently-modified neutral bacterial poly- saccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
RU2012116119A (ru) Множественная вакцинация, включающая менингококки серогруппы с
HU228384B1 (en) Vaccine compositions
JP2010516763A5 (OSRAM)
JP2015034178A (ja) 全細胞百日咳抗原を含む混合ワクチン
JP2009525260A5 (OSRAM)
JP2008525423A5 (OSRAM)
JP2004536859A5 (OSRAM)
CN107427568A (zh) 用于肺炎球菌疫苗中的免疫原性组合物
RU2007127993A (ru) Сахарид-конъюгатные вакцины
MXPA05004675A (es) Proceso de secado.
JP2009227680A5 (OSRAM)
RU2009108660A (ru) Вакцины на основе солюбилизированных и комбинированных капсулярных полисахаридов
JP2012506421A (ja) 新規な無細胞百日咳ワクチン組成物およびその製造方法
JP2010500398A5 (OSRAM)
CN104487086A (zh) 无动物源的不含酒精的疫苗组合物及其制备方法
RU2011135761A (ru) Комбинированная вакцина с цельноклеточным коклюшем
JP2011504535A5 (OSRAM)
BE1022256B1 (fr) Nouveau procede
CA3105361A1 (en) Improvements in immunogenic conjugates
KR102861088B1 (ko) 6종 혼합 액상 백신 조성물
CN110724189B (zh) 一种(1-5)-Gal-(1-6)-Man糖蛋白及其制备方法和应用
Kane et al. Immunochemistry of capsular glucans isolated from Streptococcus bovis
Smirnova et al. Vibrio cholerae strains, serogroups O 1 and O 139, as productive of major protective antigens